Rajeev Dadoo

Rajeev joined SR One in 2004 and is an alum of the Kauffman Fellows Program. His prior and current investments include Adheron, iPierian, True North, Propeller Health, Concert Pharmaceuticals, CyDex Pharmaceuticals, NeuroTherapeutics Pharma, Tranquis Therapeutics, IlluminOss Medical, and Avhana Health. Rajeev also spent time with GSK’s competitive excellence group, where he worked on company-wide strategic projects and operational projects. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked in business development at Genome Therapeutics and was a co-founder of Unimicro Technologies.

Rajeev received his BA in chemistry and mathematics from Knox College, his MBA from the Wharton School of the University of Pennsylvania, and his PhD in chemistry from Stanford University.